On humanitarian grounds the MHRA granted permission for the new Acculis pMTA product to be used to treat a liver cancer patient ahead of CE & FDA approvals expected early in the New Year.
This exciting new product in the fight against cancer is the result of a 18 month £2.6M development project undertaken by Runfold Medical on behalf of Microsulis.